Lilly and Amplitude Therapeutics announce collaboration
Amplitude Therapeutics and Lilly enter strategic collaboration to develop trans-amplifying RNA vaccines for infectious diseases.
Amplitude said initial programs target infectious diseases with high unmet need, with Lilly retaining options for up to two additional targets.
Amplitude Therapeutics said Lilly will get exclusive, target-specific rights to develop and commercialize licensed products directed to collaboration targets.
LLY•
